ClinicalTrials.Veeva

Menu
E

Erasmus University Medical Center | Erasmus Infectious Diseases

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Temozolomide
Nivolumab
Masitinib
Filgotinib
Azacitidine
Bevacizumab
Tranexamic Acid
Clazakizumab
Leuco-methylthioninium Bis(Hydromethanesulfonate)
Flecainide

Parent organization

This site is a part of Erasmus University Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 107 total trials

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granu...

Active, not recruiting
Frontotemporal Dementia
Drug: AL001
Locations recently updated

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Placebo
Drug: Volixibat

This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and...

Active, not recruiting
Frontotemporal Dementia
Drug: DNL593
Drug: Placebo

Rationale: The choice of antithrombotic regimen during TAVI and CTO PCI includes the use of unfractionated heparin. The accuracy of ACT in this setti...

Enrolling
Transcatheter Aortic Valve Replacement
Percutaneous Coronary Intervention
Diagnostic Test: activated partial thrombin time

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which tog...

Enrolling
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Drug: Allo-RevCAR01-T
Drug: R-TM123

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefi...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: Cyclophosphamide (Non-IMP)
Drug: TM123 (IMP)

Background: Intracerebral hemorrhage (ICH) accounts for 16-19% of all strokes in Western Europe and contributes profoundly to mortality and disabilit...

Enrolling
Minimally Invasive Surgical Procedures
Endoscopic Surgical Procedures
Device: Minimally invasive endoscopy-guided surgery

To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined...

Not yet enrolling
Acute Mitral Regurgitation
Device: MitraClip
Other: Optimal medical treatment

An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal dise...

Enrolling
Kidney Transplantation in Highly Sensitized Patients
Drug: Imlifidase
Other: Normal Transplantation Routine

This is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of ca...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: R-GemOx or BR plus polatuzumab vedotin
Genetic: MB-CART2019.1

The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial. A total of 2228 participants will b...

Enrolling
Coronary Artery Disease
Device: FFR guided revascularization
Device: vFFR guided revascularization

Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent...

Active, not recruiting
Persistent Atrial Fibrillation
Device: Adagio AF Cryoablation System (iCLAS™)

The IVUS CHIP trial is a post-marketing strategy study in which patients with complex coronary lesions, undergoing percutaneous coronary intervention...

Active, not recruiting
Complex Coronary Lesions
Device: IVUS
Device: Angio

To collect information about treatment for severe aortic stenosis (AS), which affects the aortic valve in the heart. Aortic stenosis is a narrowing o...

Active, not recruiting
Ventricular Outflow Obstruction
Heart Valve Diseases
Device: JenaValve Pericardial TAVR System

The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smoulde...

Enrolling
Indolent Systemic Mastocytosis
Other: Best Supportive Care
Drug: Masitinib

The purpose of this trial is to investigate the safety and efficacy of MyopiaX - a digital treatment intended to slow the progression of myopia in ch...

Active, not recruiting
Myopia
Device: Myopia control spectacles
Device: MyopiaX

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerat...

Active, not recruiting
Urinary Urgency Incontinence
Device: Neuspera Implantable Sacral Nerve Stimulation System

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. T...

Enrolling
Solid Tumor, Adult
Drug: DF1001
Drug: Sacituzumab Govitecan-hziy

This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduc...

Active, not recruiting
Heart Failure, Left Sided
Myocardial Infarction, Acute
Drug: Placebo to CDR132L
Drug: CDR132L

To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a c...

Active, not recruiting
Aortic Regurgitation
Device: JenaValve Pericardial TAVR System

Trial sponsors

Erasmus University logo
R
Celgene logo
E
AB Science logo
A
CSL Behring logo
E
G
J

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems